ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines

New CEO Amit Munshi Last Helmed Arena

 
• By Mandy Jackson

ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.

Notepad with "venture capital" written on it
ReNAgade's series A is one of the largest VC rounds so far in 2023 • Source: Shutterstock

More from Financing

More from Business